



UNICA

UNIVERSITÀ
DEGLI STUDI
DI CAGLIARI



Università di Cagliari

UNICA IRIS Institutional Research Information System

This is the Author's [*accepted*] manuscript version of the following contribution:

Cacciapaglia F, Manfredi A, Erre G, Piga M, Sakellariou G, Viapiana O, Gremese E, Spinelli FR, Atzeni F, Bartoloni E. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. *Ann Rheum Dis.* 2023 Jul;82(7):e159.

The publisher's version is available at:

[http://dx.doi.org/\[10.1136/annrheumdis-2020-218813\]](http://dx.doi.org/[10.1136/annrheumdis-2020-218813])

When citing, please refer to the published version.

Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M *et al.* The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients

Fabio Cacciapaglia,¹ Andreina Manfredi,² Gianluca Erre,³ Matteo Piga,⁴ Garifallia Sakellariou,⁵ ombretta viapiana,⁶ Elisa Gremese,^{7,8} Francesca Romana Spinelli,⁹ Fabiola Atzeni,¹⁰ Elena Bartoloni¹¹

We read with interest the paper published by Gianfrancesco *et al*¹ describing the epidemiological findings associated with hospitalisation for COVID-19 in 600 patients with rheumatic diseases. Multivariate adjusted models proved a significant increased risk of hospitalisation for older age (>65 years), prednisone doses of ≥ 10 mg/day and presence of comorbidities, such as cardiovascular (CV) and lung diseases or diabetes. The use of biological or targeted synthetic disease-modifying antirheumatic drug (DMARD) appeared to decrease hospitalisation risk.

Underlying CV comorbidities seem to increase the susceptibility to SARS-CoV-

2 infection and to contribute to myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism also in non-rheumatic patients.^{2,3} Pathophysiological mechanisms underlying cardiac injury in patients with SARS-CoV-

2 infection are poorly understood. However, biological features of SARS-CoV-2 and its interaction with the immune system seem to have a pivotal role in organ damage and, in particular, in CV manifestations.³

Clinical and demographic characteristics of patients with rheumatic disease suffering from COVID-19 have been explored by several Italian groups, with the highest number of COVID-19 cases observed in the North, particularly in Lombardy. In this setting, Fredi *et al*, on behalf of the Brescia Rheumatology COVID-19 Study Group,⁴ confirmed that patients with COVID-19 were older and more likely to have arterial hypertension and obesity, while no association with CV disease was reported by Monti *et al*⁵ in 320 cases observed

in Pavia.

The *Cardiovascular and Obesity and Rheumatic Diseases* (CORDIS) Study Group of the Italian Society of Rheumatology is an ongoing longitudinal observational study aiming to assess CV comorbidity and related risk factors in patients with chronic rheumatic diseases. Since January 2019, a prospective unselected cohort of patients with rheumatoid arthritis (RA) fulfilling the 2010 European League Against Rheumatism/American College of Rheumatology classification criteria, recruited in 10 University tertiary Italian Centres, has been included in the study. Demographic, clinical and serologic features, as well as ongoing treatment, were collected, and CV risk was estimated by the European cardiovascular disease risk assessment model Systematic COronary Risk Evaluation (SCORE) chart.

From 25 February to 15 July 2020, we assessed the incidence and outcomes of SARS-CoV-2 infection in our cohort, during the outpatient visit or by telemedicine visit. The prevalence of COVID-19 in general reference population was taken from the WHO website (<http://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>).

We compared the study population with the general reference population by Fisher's exact test. A p value of <0.05 was considered significant. The OR was then calculated with 95% CI. As part of the GISEA Registry, the study was approved by all local ethics committees.

Overall, 1471 patients with RA (78.5% female; mean age 60 ± 11 years; median disease duration 115 (IQR 150–186) months) were included in the analysis. The median (IQR) 10-year

CV risk by SCORE algorithm was 0.8% (0.2–2.4), and 84 (6%) patients presented a high CV SCORE risk ($\geq 5\%$).

We recorded six cases of SARS-CoV-2 infection confirmed

by nasal pharyngeal swab ([table 1](#)); the incidence of SARS-CoV-

2 infection was 4.08/1000 patients, similar to that observed in the overall Italian population. All infected patients had a disease duration >10 years and were overweight, four were affected by hypertension and/or dyslipidaemia, two by diabetes mellitus and one patient reported smoke habit. The median 10-year

CV SCORE risk was 1.5 (IQR 0.5–5.75).

Three patients were hospitalised for interstitial pneumonia and all completely recovered within 3 weeks.

Patients older than 65 years had a significant higher risk of

SARS-CoV-

2 infection (OR 10.1 (95%CI 1.4 to 119), p=0.01).

Interestingly, patients with a high SCORE risk ($\geq 5\%$) had an eightfold increased risk of infection (OR 8.2 (95%CI 1.5 to 35.5), p=0.04). Finally, biologic DMARD treatment did not significantly increase the risk of SARS-CoV-

2 infection (OR 7 (95%CI 0.98 to 83), p=0.08).

The results of the present analysis demonstrated that the overall incidence of COVID-19 infection in a large cohort of patients with RA from different Italian regions is comparable with the general population; moreover, our data confirmed an increased risk of COVID-19 infection in patients older than 65 years, with long-standing disease and CV comorbidity, particularly in patients with a high 10-year SCORE CV risk. We also confirmed that ongoing treatment with biological therapies would not seem to affect the risk of infection in these patients, as reported in other Italian cohorts.⁶

Although the added value of the study by Gianfrancesco *et al*¹ was the identification of risk factors for hospitalisation in patients with rheumatic diseases, we believe that some points deserve further attention in these patients.⁷ In particular, considering dissimilar patients' behaviours and adherence to recommendations to avoid social contacts⁸ as well as the high proportion of asymptomatic subjects, large serological studies may help estimate the real spread of SARS-CoV-2 infection in patients with rheumatic diseases. Our data could also suggest further investigation on mechanisms underlying the increased risk and worst CV outcome of patients with rheumatic disorders infected by SARS-CoV-2.